Effect of food, antacid, and age on the pharmacokinetics of the oral thrombin receptor antagonist vorapaxar (sch 530348) in healthy volunteers

Clinical Pharmacology in Drug Development

Volumn 2, Issue 3, 2013, Pages 223-230

  Kosoglou, Teddy ^a   Reyderman, Larisa ^a   Tseng, Jack ^a   Kumar, Bharath ^a   Xuan, Fengjuan ^a   Schiller, James ^a   Meehan, Alan G ^a   Kim, Kenneth ^b   Cutler, David L ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b WCCT Global   (United States)

Author keywords

Age; Antacid; Food; Interaction; Pharmacokinetics; SCH 530348; Vorapaxar

Indexed keywords

ALUMINUM MAGNESIUM HYDROXIDE; ANTACID AGENT; GAVISCON; VORAPAXAR;

ADULT; AGE; AGED; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG EXPOSURE; DRUG INDUCED HEADACHE; DRUG INHIBITION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOOD DRUG INTERACTION; FOOD INTAKE; HUMAN; HUMAN EXPERIMENT; INFLUENZA; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; RHINOPHARYNGITIS; SINGLE DRUG DOSE; SORE THROAT; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT;

EID: 84892488797     PISSN: 2160763X     EISSN: 21607648     Source Type: Journal    
DOI: 10.1002/cpdd.30     Document Type: Article

References (9)

1. Chackalamannil S, Wang Y, Greenlee WJ, et al. Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J Med Chem. 2008; 51:3061-3064.
2. Chintala M, Shimizu K, Ogawa M, Yamaguchi H, Doi M, Jensen P. Basic and translational research on proteinase-activated receptors: antagonism of the proteinase-activated receptor 1 for thrombin, a novel approach to antiplatelet therapy for atherothrombotic disease. J Pharmacol Sci. 2008; 108:433-438.
3. Kosoglou T, Reyderman L, Kasserra C. Optimizing dose of the novel thrombin receptor antagonist SCH 530348 based on pharmacodynamics and pharmacokinetics in healthy subjects [abstract]. Clin Pharmacol Ther. 2008; 83.
4. Kosoglou T, Reyderman L, Kasserra C, et al. No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects. Eur J Clin Pharmacol. 2012; 68:291-300.
5. Kosoglou T, Reyderman L, Tiessen RG, et al. Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects. Eur J Clin Pharmacol. 2012; 68:249-258.
6. Gilchrist IC, O'Shea JC, Kosoglou T, et al. Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention. Circulation. 2001; 104:406-411.
7. Behm MO, Kosoglou T, Miltenburg AMM, et al. The effect of food on the single dose pharmacokinetics of the PAR-1 antagonist vorapaxar in healthy subjects [abstract 1393295]. Clin Pharmacol in Drug Develop 2012; 1(4):220.
8. Becker RC, Moliterno DJ, Jennings LK, et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet. 2009; 373:919-928.
9. Goto S, Yamaguchi T, Ikeda Y, Yamaguchi H, Shimizu K, Jensen P. Phase II trial of the novel antiplatelet agent, SCH 530348, in Japanese patients with non-ST segment elevation acute coronary syndromes (NSTE ACS) [abstract]. Eur Heart J. 2008; 29:829.